Patient characteristics
| Baseline characteristics . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Age, y/sex | 50/M | 62/F | 59/M |
| Duration of CLL, y | 8 | 4 | 16 |
| Previous treatment | None | CD 40 ligand-transfected autologous lymphocytes 24 months ago | Multiple courses of fludarabine, 1994-2000 Rituximab 1 dose 6 mo ago |
| Baseline CBC | |||
| WBC, μL | 704 000 | 207 000 | 58 800 |
| Hemoglobin, g/dL | 9.1 | 7.0 | 10.1 |
| Platelets, μL | 120 000 | 135 000 | 80 000 |
| Stage (Rai) | III | III | IV |
| Current fludarabine cycles before ITP | 3 | 1 | 3 |
| ITP onset from last fludarabine cycle, d | 5 | 9 | 12 |
| Platelet nadir, μL | 4 000 | 1 000 | 3 000 |
| ITP clinical manifestations | Epistaxis, buccal hematoma, petechiae | Epistaxis, palatal petechiae | Palatal and skin petechiae |
| Serum platelet antibody | GPIb and GPIIb/IIIa | GPIb | Negative |
| ITP treatment | Prednisone | Prednisone | Prednisone |
| IVIG (Gammar) | IVIG (Sandoglobulin) | IVIG (Polygam SD) | |
| Win Rho | Rituximab | Rituximab | |
| Rituximab | |||
| Response to rituximab, μL | Complete response | Complete response | Partial response |
| Platelets 291 000 | Platelets 267 000 | Platelets 72 000 | |
| Duration of response, mo | 17+ | 6+ | 6 |
| Baseline characteristics . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Age, y/sex | 50/M | 62/F | 59/M |
| Duration of CLL, y | 8 | 4 | 16 |
| Previous treatment | None | CD 40 ligand-transfected autologous lymphocytes 24 months ago | Multiple courses of fludarabine, 1994-2000 Rituximab 1 dose 6 mo ago |
| Baseline CBC | |||
| WBC, μL | 704 000 | 207 000 | 58 800 |
| Hemoglobin, g/dL | 9.1 | 7.0 | 10.1 |
| Platelets, μL | 120 000 | 135 000 | 80 000 |
| Stage (Rai) | III | III | IV |
| Current fludarabine cycles before ITP | 3 | 1 | 3 |
| ITP onset from last fludarabine cycle, d | 5 | 9 | 12 |
| Platelet nadir, μL | 4 000 | 1 000 | 3 000 |
| ITP clinical manifestations | Epistaxis, buccal hematoma, petechiae | Epistaxis, palatal petechiae | Palatal and skin petechiae |
| Serum platelet antibody | GPIb and GPIIb/IIIa | GPIb | Negative |
| ITP treatment | Prednisone | Prednisone | Prednisone |
| IVIG (Gammar) | IVIG (Sandoglobulin) | IVIG (Polygam SD) | |
| Win Rho | Rituximab | Rituximab | |
| Rituximab | |||
| Response to rituximab, μL | Complete response | Complete response | Partial response |
| Platelets 291 000 | Platelets 267 000 | Platelets 72 000 | |
| Duration of response, mo | 17+ | 6+ | 6 |